Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 3Recruiting 2Completed 2Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 5INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Other hematologic neoplasm 1

Conditions

Recurrence 1Metastatic Solid Tumors 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1

Interventions

pembrolizumab 241Carboplatin 167Injections 138Paclitaxel 119Gemcitabine 116Bevacizumab 112Cisplatin 105Docetaxel 82Cyclophosphamide 78Pemetrexed 76Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 57fludarabine 55Nivolumab 55Leucovorin 52Cetuximab 52130-nm albumin-bound paclitaxel 47Dexamethasone 46Rituximab 41atezolizumab 37venetoclax 35Drug Therapy 35toripalimab 34enzalutamide 34Irinotecan 34durvalumab 32Prednisone 32Letrozole 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × Infusions, Intravenous × Clear all
NCT07108114 2026-02-23

SLV-324 Treatment of Metastatic Solid Tumors

Solve Therapeutics

Phase 1 Recruiting
70 enrolled
Other solid neoplasm

Metastatic Solid Tumors

NCT03850574 2025-08-26

TUSCANY

Aptose Biosciences Inc.

Phase 1/2 Recruiting
240 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡